MedicineOncologySurgeryChemotherapyNeuro-oncologyTumor HeterogeneityBrain TumorsGlioblastomaNeuro-oncologic PathologyPostoperative Radiotherapy For Brain TumorsPrimary Brain Tumor RadiotherapyRecurrent Brain TumorsAstrocytoma PathologyGlioblastoma ChemotherapyGlioblastoma Molecular SubtypesGlioblastoma PathologyGlioblastoma Postoperative RadiotherapyGlioblastoma SurgeryGlioblastoma Therapeutic ResistanceWho Grading Classification
Glioblastoma multiforme (GBM) or astrocytoma grade IV on WHO classification is the most aggressive and the most frequent of all primary brain tumors. Glioblastoma is multiforme, resistant to therapeutic interventions illustrating the heterogeneity exhibited by this tumor in its every aspect, including clinical presentation, pathology, genetic signature. Current data and treatment strategy in GBM are presented focusing on basic science data and key clinical aspects like surgery, including personal experience; adjuvant modalities: radiotherapy, chemotherapy, but also for experimental approaches. Therapeutic attitude in recurrent GBM is also widely discussed.
27
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text
Mutations in the p53 gene occur in diverse human tumour types
Janice Nigro, Suzanne J. Baker, Antonette C. Preisinger et al. · Nature · 1989 · 2.8K citations · Full text
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa, James S. Waldron, Amith Panner et al. · Nature Medicine · 2006 · 1.4K citations
Medicine, Cancer Biology, Oncology +14